By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



3334 East Coast Hwy 157

Corona del Mar  California  92625  U.S.A.
Phone: 949-721-4063 Fax: 949-760-1030



Company News
Leader In Cure, Care And Community For Duchenne Muscular Dystrophy CureDuchenne Launches New Website 3/28/2017 7:26:02 AM
Eighth Annual Champions To CureDuchenne Gala Presented By Fired Up Charity Foundation To Be Held April 8 At University of Texas Golf Club 3/22/2017 7:13:40 AM
BioMarin (BMRN) Release: Biotech Transfers Duchenne Natural History Database To CureDuchenneTo Improve Knowledge Of Duchenne Patients And Improve Clinical Outcomes 1/10/2017 8:35:13 AM
CureDuchenne Release: Non-Profits, Pharmaceutical Companies And Noted Clinicians Collaborate To Launch The Collaborative Trajectory Analysis Project (Ctap); Advancing Clinical Trial Design For Duchenne Muscular Dystrophy 10/25/2016 9:02:35 AM
CureDuchenne's Early Stage Investment In Bamboo Therapeutics Accelerates Gene Therapy For Duchenne, Bamboo Acquired By Pfizer (PFE) 8/1/2016 11:06:14 AM
CureDuchenne And Catabasis (CATB) To Host A Webinar To Review Information On Edasalonexent (CAT-1004) And The MoveDMD Trial On June 22, 2016 6/14/2016 8:22:44 AM
Bamboo Therapeutics And CureDuchenne To Host A Webinar On Developing Gene Therapy For Duchenne Muscular Dystrophy On June 13, 2016 6/2/2016 11:02:38 AM
CureDuchenne Responds To FDA Decision On Drisapersen For Duchenne Muscular Dystrophy 1/14/2016 8:56:52 AM
Capricor Therapeutics, Inc. And CureDuchenne To Host Webinar On November 3, 2015 At 3:00 p.m. ET 10/30/2015 9:22:11 AM
CureDuchenne’s Funding Bears Fruit With Drisapersen: First-Ever New Drug Application (NDA) Accepted By FDA For Duchenne Muscular Dystrophy 6/29/2015 10:44:49 AM